A CB 1/CB 2 receptor agonist, WIN 55,212-2, exerts its therapeutic effect in a viral autoimmune model of multiple sclerosis by restoring self-tolerance to myelin

Neuropharmacology

Volumn 63, Issue 3, 2012, Pages 385-393

  Arevalo Martin, Angel ^a   Molina Holgado, Eduardo ^a   Guaza, Carmen ^b  

^a HOSPITAL NACIONAL DE PARAPLÉJICOS   (Spain)

^b INSTITUTO CAJAL   (Spain)

Author keywords

Cyclophosphamide; DTH; Foxp3; IL 6; TMEV; Treg

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CHEMOKINE; CYTOKINE; MYELIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ CD25+ FOXP3+ T LYMPHOCYTE; CD4+ CD25+ FOXP3- T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; IMMUNOLOGICAL TOLERANCE; MOTOR DYSFUNCTION; MOUSE; MULTIPLE SCLEROSIS; MURINE ENCEPHALOMYELITIS VIRUS; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RELAPSE; SPLEEN CELL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ADOPTIVE TRANSFER; ANIMALS; AUTOIMMUNE DISEASES; BENZOXAZINES; CHEMOKINES; CYTOKINES; FEMALE; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; HYPERSENSITIVITY, DELAYED; IMMUNOHISTOCHEMISTRY; LYMPH NODES; MICE; MORPHOLINES; MOTOR ACTIVITY; MULTIPLE SCLEROSIS; MYELIN SHEATH; NAPHTHALENES; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; SELF TOLERANCE; SPLEEN; T-LYMPHOCYTES;

EID: 84862021462     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2012.04.012     Document Type: Article

References (50)

1. A. Arevalo-Martin, J.M. Vela, E. Molina-Holgado, J. Borrell, and C. Guaza Therapeutic action of cannabinoids in a murine model of multiple sclerosis J. Neurosci. 23 2003 2511 2516
2. D. Baker, and G. Pryce The endocannabinoid system and multiple sclerosis Curr. Pharm. Des. 14 2008 2326 2336
3. D. Baker, G. Pryce, J.L. Croxford, P. Brown, R.G. Pertwee, J.W. Huffman, and L. Layward Cannabinoids control spasticity and tremor in a multiple sclerosis model Nature 404 2000 84 87
4. C. Benito, J.P. Romero, R.M. Tolón, D. Clemente, F. Docagne, C.J. Hillard, C. Guaza, and J. Romero Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis J. Neurosci. 27 2007 2396 2402
5. A. Cabranes, K. Venderova, E. de Lago, F. Fezza, A. Sánchez, L. Mestre, M. Valenti, A. Garcia-Merino, J.A. Ramos, V. Di Marzo, and J. Fernández-Ruiz Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis Neurobiol. Dis. 20 2005 207 217
6. D. Centonze, M. Bari, S. Rossi, C. Prosperetti, R. Furlan, F. Fezza, V. De Chiara, L. Battistini, G. Bernardi, S. Bernardi, G. Martino, and M. Maccarrone The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis Brain 130 2007 2543 2553
7. L. Chatenoud, J. Primo, and J.F. Bach CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice J. Immunol. 158 1997 2947 2954
8. M. Comabella, and R. Martin Genomics in multiple sclerosis: current state and future directions J. Neuroimmunol. 187 2007 1 8
9. J.L. Croxford, and S.D. Miller Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R+WIN55,212 J. Clin. Invest. 111 2003 1231 1240
10. J.L. Croxford, G. Pryce, S.J. Jackson, C. Ledent, G. Giovannoni, R.G. Pertwee, T. Yamamura, and D. Baker Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis J. Neuroimmunol. 193 2008 120 129
11. M.C. Dal Canto, and H.L. Lipton Multiple sclerosis. Animal model: Theiler's virus infection in mice Am. J. Pathol. 88 1977 497 500
12. E. de Lago, M. Moreno-Martet, A. Cabranes, Ramos. J.A, and J. Fernandez-Ruiz Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB(1) receptor-mediated anti-inflammatory effects Neuropharmacology 62 2012 2298 2307
13. K. Eller, D. Wolf, J.M. Huber, M. Metz, G. Mayer, A.N. McKenzie, M. Maurer, A.R. Rosenkranz, and A.M. Wolf IL-9 production by regulatory T cells recruits mast cells that are essential for regulatory T cell-induced immune suppression J. Immunol. 186 2011 83 91
14. S. Galiegue, S. Mary, J. Marchand, D. Dussossoy, D. Carriere, S. Carayon, M. Bouaboula, D. Shire, G. Le Fur, and P. Casellas Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations Eur. J. Biochem. 232 1995 54 61
15. Y. Gaoni, and R. Mechoulam Isolation, structure, and partial synthesis of an active constituent of hashish J. Am. Chem. Soc. 86 1964 1646 1647
16. A. Jäger, V. Dardalhon, R.A. Sobel, E. Bettelli, and V.K. Kuchroo Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes J. Immunol. 183 2009 7169 7177
17. R.T. Johnson The virology of demyelinating diseases Ann. Neurol. 36 Suppl. 1994 S54 S60
18. Y. Katz-Levy, K.L. Neville, J. Padilla, S. Rahbe, W.S. Begolka, A.M. Girvin, J.K. Olson, C.L. Vanderlugt, and S.D. Miller Temporal development of autoreactive Th1 responses and endogenous presentation of self myelin epitopes by central nervous system-resident APCs in Theiler's virus-infected mice J. Immunol. 165 2000 5304 5314
19. T.W. Klein, C. Newton, and H. Friedman Cannabinoid receptors and immunity Immunol. Today 19 1998 373 381
20. T.W. Klein Cannabinoid-based drugs as anti-inflammatory therapeutics Nat. Rev. Immunol. 5 2005 400 411
21. + regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis J. Immunol. 169 2002 4712 4716
22. T. Korn, J. Reddy, W. Gao, E. Bettelli, A. Awasthi, T.R. Petersen, B.T. Bäckström, R.A. Sobel, K.W. Wucherpfennig, T.B. Strom, M. Oukka, and V.K. Kuchroo Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation Nat. Med. 13 2007 423 431
23. J.F. Kurtzke Epidemiologic evidence for multiple sclerosis as an infection Clin. Microbiol. Rev. 6 1993 382 427
24. H.L. Lipton, and M.C. Dal Canto Theiler's virus-induced demyelination: prevention by immunosuppression Science 192 1976 62 64
25. A. Lledó, J. Borrell, and C. Guaza Dexamethasone regulation of interleukin-1-receptors in the hippocampus of Theiler's virus-infected mice: effects on virus-mediated demyelination Eur. J. Pharmacol. 372 1999 75 83
26. A. Lourbopoulos, N. Grigoriadis, R. Lagoudaki, O. Touloumi, E. Polyzoidou, I. Mavromatis, N. Tascos, A. Breuer, H. Ovadia, D. Karussis, E. Shohami, R. Mechoulam, and C. Simeonidou Administration of 2- arachidonoylglycerol ameliorates both acute and chronic experimental autoimmune encephalomyelitis Brain Res. 1390 2011 126 141
27. W.D. Lyman, J.R. Sonett, C.F. Brosnan, R. Elkin, and M.B. Bornstein Delta 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis J. Neuroimmunol. 23 1989 73 81
28. K. Maresz, G. Pryce, E.D. Ponomarev, G. Marsicano, J.L. Croxford, L.P. Shriver, C. Ledent, X. Cheng, E.J. Carrier, M.K. Mann, G. Giovannoni, R.G. Pertwee, T. Yamamura, N.E. Buckley, C.J. Hillard, B. Lutz, D. Baker, and B.N. Dittel Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells Nat. Med. 13 2007 492 497
29. L. Mestre, F. Correa, A. Arevalo-Martin, E. Molina-Holgado, M. Valenti, G. Ortar, V. Di Marzo, and C. Guaza Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis J. Neurochem. 92 2005 1327 1339
30. S.D. Miller, B.L. McRae, C.L. Vanderlugt, K.M. Nikcevich, J.G. Pope, L. Pope, and W.J. Karpus Evolution of the T-cell repertoire during the course of experimental immune-mediated demyelinating diseases Immunol. Rev. 144 1995 225 244
31. S.D. Miller, C.L. Vanderlugt, W.S. Begolka, W. Pao, R.K. Yauch, K.L. Neville, Y. Katz-Levy, A. Carrizosa, and B.S. Kim Persistent infection with Theiler's virus leads to CNS autoimmunity via epitope spreading Nat. Med. 3 1997 1133 1136
32. C.A. Newton, T.W. Klein, and H. Friedman Secondary immunity to Legionella pneumophila and Th1 activity are suppressed by delta-9-tetrahydrocannabinol injection Infect. Immun. 62 1994 4015 4020
33. + regulatory T cells in antitumor immune response J. Immunol. 175 2005 4433 4440
34. E.C. Nowak, C.T. Weaver, H. Turner, S. Begum-Haque, B. Becher, B. Schreiner, A.J. Coyle, L.H. Kasper, and R.J. Noelle IL-9 as a mediator of Th17-driven inflammatory disease J. Exp. Med. 206 2009 1653 1660
35. M. Nygardas, C. Aspelin, H. Paavilainen, M. Röyttä, M. Waris, and V. Hukkanen Treatment of experimental autoimmune encephalomyelitis in SJL/J mice with a replicative HSV-1 vector expressing interleukin-5 Gene Ther. 18 2011 646 655
36. S. Ortega-Gutiérrez, E. Molina-Holgado, A. Arevalo-Martin, F. Correa, A. Viso, M.L. López-Rodríguez, V. Di Marzo, and C. Guaza Activation of the endocannabinoid system as therapeutic approach in a murine model of multiple sclerosis FASEB J. 19 2005 1338 1340
37. J. Palazuelos, N. Davoust, B. Julien, E. Hatterer, T. Aguado, R. Mechoulam, C. Benito, J. Romero, A. Silva, M. Guzmán, S. Nataf, and I. Galve-Roperh The CB(2) cannabinoid receptor controls myeloid progenitor trafficking: involvement in the pathogenesis of an animal model of multiple sclerosis J. Biol. Chem. 283 2008 13320 13329
38. R. Pandey, V.L. Hegde, M. Nagarkatti, and P.S. Nagarkatti Targeting cannabinoid receptors as a novel approach in the treatment of graft-versus-host disease: evidence from an experimental murine model J. Pharmacol. Exp. Ther. 338 2011 819 828
39. + T cell-mediated suppression by dendritic cells Science 299 2003 1033 1036
40. D. Piomelli The molecular logic of endocannabinoid signalling Nat. Rev. Neurosci. 4 2003 873 884
41. M. Rodriguez, E. Oleszak, and J. Leibowitz Theiler's murine encephalomyelitis: a model of demyelination and persistence of virus Crit. Rev. Immunol. 7 1987 325 365
42. S. Sakaguchi, T. Yamaguchi, T. Nomura, and M. Ono Regulatory T cells and immune tolerance Cell 133 2008 775 787
43. M.L. Salem, A.N. Kadima, S.A. El-Naggar, M.P. Rubinstein, Y. Chen, W.E. Gillanders, and D.J. Cole Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells J. Immunother. 30 2007 40 53
44. B. Sawitzki, C.L. Kingsley, V. Oliveira, M. Karim, M. Herber, and K.J. Wood IFN-gamma production by alloantigen-reactive regulatory T cells is important for their regulatory function in vivo J. Exp. Med. 201 2005 1925 1935
45. + T cell regulatory functions J. Immunol. 178 2007 271 279
46. E. Wiesemann, J. Klatt, C. Wenzel, F. Heidenreich, and A. Windhagen Correlation of serum IL-13 and IL-5 levels with clinical response to Glatiramer acetate in patients with multiple sclerosis Clin. Exp. Immunol. 133 2003 454 460
47. I. Wirguin, R. Mechoulam, A. Breuer, E. Schezen, J. Weidenfeld, and T. Brenner Suppression of experimental autoimmune encephalomyelitis by cannabinoids Immunopharmacology 28 1994 209 214
48. A. Witting, L. Chen, E. Cudaback, A. Straiker, L. Walter, B. Rickman, T. Möller, C. Brosnan, and N. Stella Experimental autoimmune encephalomyelitis disrupts endocannabinoid-mediated neuroprotection Proc. Natl. Acad. Sci. U S A 103 2006 6362 6367
49. K.W. Wucherpfennig, and J.L. Strominger Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein Cell 80 1995 695 705
50. -CD4 T cells constitute a reservoir of committed regulatory cells that regain CD25 expression upon homeostatic expansion Proc. Natl. Acad. Sci. 102 2005 4091 4096